Opportunities and challenges for the implementation of pharmacogenomics in supportive care for gastrointestinal cancer patients in Zimbabwe.

IF 1.6 4区医学 Q3 PHARMACOLOGY & PHARMACY

Pharmacogenomics Pub Date : 2025-10-01 Epub Date: 2025-12-09 DOI:10.1080/14622416.2025.2600695

Tinashe Adrian Mazhindu, Ntokozo Ndlovu, Margaret Z Borok, Kevin Grimes, Collen Masimirembwa

{"title":"Opportunities and challenges for the implementation of pharmacogenomics in supportive care for gastrointestinal cancer patients in Zimbabwe.","authors":"Tinashe Adrian Mazhindu, Ntokozo Ndlovu, Margaret Z Borok, Kevin Grimes, Collen Masimirembwa","doi":"10.1080/14622416.2025.2600695","DOIUrl":null,"url":null,"abstract":"Introduction: Supportive care in oncology aims to prevent and manage cancer-related side effects. This study reviews supportive medications for gastrointestinal cancer patients, analyzes usage patterns, biomarker frequencies, and feasibility of dose adjustments.Methodology: A 10-year retrospective study was performed at Parirenyatwa group of Hospitals, Radiotherapy & Oncology Center evaluating the supportive care medicines prescribed for all gastrointestinal cancer patients.Results: A total of 607 patients were analyzed, 42% receiving cancer-specific treatment and 58% best supportive care. Patients who receive cancer-specific treatment, 200 participants (78%) received at least one supportive care medicine compared to 250 (71%) in the best supportive care group (OR 1.4; 95% CI 0.96-2; p = 0.08).Seventeen different supportive care medications were prescribed, seven (41%) of these have pharmacogenomic biomarkers testing recommendation. More patients in the cancer-treated group received medicines with actionable pharmacogenomic biomarkers than in the best supportive care group (56% versus 40%; OR 1.9; 95% CI 1.38-2.66; p = 0.0001). PGX guidelines were fully implemented for tramadol, codeine, omeprazole, and ondansetron; partially for ibuprofen and celecoxib; and unimplementable for amitriptyline.Conclusion: There is an opportunity to improve supportive care in gastrointestinal cancer patients through pharmacogenomics though some specific medicines challenges to full implementations are due to limited registered medicines.","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"605-613"},"PeriodicalIF":1.6000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12773547/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14622416.2025.2600695","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/12/9 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Supportive care in oncology aims to prevent and manage cancer-related side effects. This study reviews supportive medications for gastrointestinal cancer patients, analyzes usage patterns, biomarker frequencies, and feasibility of dose adjustments.

Methodology: A 10-year retrospective study was performed at Parirenyatwa group of Hospitals, Radiotherapy & Oncology Center evaluating the supportive care medicines prescribed for all gastrointestinal cancer patients.

Results: A total of 607 patients were analyzed, 42% receiving cancer-specific treatment and 58% best supportive care. Patients who receive cancer-specific treatment, 200 participants (78%) received at least one supportive care medicine compared to 250 (71%) in the best supportive care group (OR 1.4; 95% CI 0.96-2; p = 0.08).Seventeen different supportive care medications were prescribed, seven (41%) of these have pharmacogenomic biomarkers testing recommendation. More patients in the cancer-treated group received medicines with actionable pharmacogenomic biomarkers than in the best supportive care group (56% versus 40%; OR 1.9; 95% CI 1.38-2.66; p = 0.0001). PGX guidelines were fully implemented for tramadol, codeine, omeprazole, and ondansetron; partially for ibuprofen and celecoxib; and unimplementable for amitriptyline.

Conclusion: There is an opportunity to improve supportive care in gastrointestinal cancer patients through pharmacogenomics though some specific medicines challenges to full implementations are due to limited registered medicines.

查看原文本刊更多论文

津巴布韦胃肠癌患者支持性护理中实施药物基因组学的机遇和挑战。

简介：肿瘤学的支持性护理旨在预防和管理癌症相关的副作用。本研究回顾了胃肠道癌症患者的支持药物，分析了使用模式、生物标志物频率和剂量调整的可行性。方法：在Parirenyatwa医院放射与肿瘤中心进行为期10年的回顾性研究，评估所有胃肠道肿瘤患者的支持性护理药物处方。结果：共分析607例患者，42%接受癌症特异性治疗，58%接受最佳支持治疗。接受癌症特异性治疗的患者中，200名参与者（78%）接受了至少一种支持治疗药物，而在最佳支持治疗组中，250名参与者（71%）接受了至少一种支持治疗药物（OR 1.4; 95% CI 0.96-2; p = 0.08）。17种不同的支持性治疗药物被处方，其中7种（41%）具有药物基因组学生物标志物测试推荐。与最佳支持治疗组相比，癌症治疗组更多的患者接受了具有可操作药物基因组学生物标志物的药物（56% vs 40%; OR 1.9; 95% CI 1.38-2.66; p = 0.0001）。曲马多、可待因、奥美拉唑和昂丹西琼的PGX指南得到了全面实施；部分用于布洛芬和塞来昔布；阿米替林是不可行的。结论：通过药物基因组学改善胃肠道肿瘤患者的支持性护理是有机会的，尽管由于注册药物有限，一些特定药物难以全面实施。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacogenomics 医学-药学

CiteScore

3.40

自引率

9.50%

发文量

审稿时长

4-8 weeks

期刊介绍： Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.